VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Wuliangye Yibin Co., Ltd. vs Bristol-Myers Squibb Company
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Wuliangye Yibin Co., Ltd.
000858 · Shenzhen Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Wuliangye Yibin Co., Ltd.'s moat claims, evidence, and risks.
View 000858 analysisBristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisComparison highlights
- Moat score gap: Wuliangye Yibin Co., Ltd. leads (80 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Wuliangye Yibin Co., Ltd. has 3 segments (76.1% in Wuliangye-branded Baijiu products); Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: Wuliangye Yibin Co., Ltd. has 5 moat types across 3 domains; Bristol-Myers Squibb Company has 4 across 3.
Primary market context
Wuliangye Yibin Co., Ltd.
Wuliangye-branded Baijiu products
China baijiu market (sales revenue; producers above designated size)
China
Consumers (premium gifting/banqueting; affluent households)
Branded spirits producer and marketer
76.1%
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
Side-by-side metrics
Moat coverage
Shared moat types
Wuliangye Yibin Co., Ltd. strengths
Bristol-Myers Squibb Company strengths
Segment mix
Wuliangye Yibin Co., Ltd. segments
Full profile >Wuliangye-branded Baijiu products
Oligopoly
Other liquor products (Wuliang NongXiang and other series)
Competitive
Non-liquor products (other)
Competitive
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.